Carelon Policy Expansion Drives Genome Testing Revenue and Reimbursement Rates
What happened
Carelon expanded its coverage policy, which led to increased genome collection rates. GeneDx reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook. The company noted that while demand remained strong, requiring more payer documentation before testing began slowed the movement of some orders through the lab.
From themarketsdaily.com
Why it matters
The policy expansion resulted in better genome collections for GeneDx, which increased its blended average reimbursement rate by approximately 5% to $3,436 per test. This shift toward exome testing, which has a higher contracted rate, contributed to GeneDx's improved adjusted gross margin.
The American Academy of Pediatrics recommends using exome and genome testing as first-line diagnostic care.
From themarketsdaily.com
Who's involved
- CarelonHealth services company whose expanded coverage policy drove increased genome collection rates
- Elevance Health, Inc.Parent company of Carelon
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Quest DiagnosticsSpeculative
Increased genome testing demand might strengthen Quest Diagnostics' market position against competitors.
- CVS HealthSpeculative
CVS Health might face increased pressure on sales and pricing within the U.S. health insurance sector due to competition with Carelon.
Keep exploring
The entities involved
-
Carelon
health services company, subsidiary of Elevance Health (formerly Anthem)